Organization
Pfizer Inc, Inflammation and Immunology, Montreal, QC, Canada
2 abstracts
Abstract
ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFTOrg: Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, United States of America, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, Pfizer Inc, Inflammation and Immunology, Montreal, QC, Canada,
Abstract
ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIBOrg: Central Connecticut Dermatology Research, Cromwell, CT, United States of America, Charité Universitätsmedizin, Department of Rheumatology, Infectious Diseases and Rheumatology, Berlin, Germany, German Rheumatism Research Center Berlin, Epidemiology, Berlin, Germany, Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of America, Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America,